Literature DB >> 30390367

Cerebral MR oximetry during acetazolamide augmentation: Beyond cerebrovascular reactivity in hemodynamic failure.

Christopher Leatherday1, Seena Dehkharghani2, Fadi Nahab3, Jason W Allen1,3, Junjie Wu1, Ranliang Hu1, Deqiang Qiu1.   

Abstract

BACKGROUND: Oxygen extraction fraction (OEF) elevation predicts increased ischemic stroke incidence among patients with carotid steno-occlusive disease, and can be estimated from quantitative susceptibility mapping (QSM) MRI.
PURPOSE: To explore QSM oximetry during acetazolamide (ACZ) challenge, hypothesizing that detectable OEF alterations will reflect hemodynamic compromise in unilateral cerebrovascular disease (CVD) patients. STUDY TYPE: Retrospective.
SUBJECTS: Fourteen unilateral CVD patients, and 24 healthy controls (HC). FIELD STRENGTH/SEQUENCE: Multiecho gradient echo (GRE) and T1 -weighted images at 3T. ASSESSMENT: We constructed QSM images and R2* maps from multiecho GRE images. QSM-OEF maps were generated from the susceptibility difference between venous blood and background brain tissue. Intrasubject diseased/contralateral hemisphere OEF ratios in the middle cerebral artery (MCA) territories were calculated. Intravascular susceptibility in the straight sinus (SS) and MCA was also measured. STATISTICAL TESTS: The result significance was determined using t-tests and Pearson's correlation.
RESULTS: Mean and standard deviation for the patient diseased/contralateral OEF ratios were 1.15 ± 0.14 at baseline and 1.23 ± 0.17 post-ACZ. Disease group R2* ratios were 0.95 ± 0.05 at baseline and 1.03 ± 0.08 post-ACZ. Left/right OEF and R2* ratios for the HC group were 0.98 ± 0.06 and 0.99 ± 0.038, respectively. Susceptibility (ppb) in the SS and MCA in patients was 162.63 ± 35.4 and -22.33 ± 13.70, respectively, at baseline, 124.56 ± 37.43 and -19.27 ± 23.14 post-ACZ. The HC group SS and MCA susceptibility was 146.10 ± 24.79 and -19.59 ± 12.37, respectively. Patient group OEF ratios were greater than 1.0 before and after ACZ challenge (P < 0.01 and < 0.001, respectively, one-sample t-test), and were greater than HC ratios (P < 0.001 unpaired t-test). OEF and R2* ratios increased from baseline to post-ACZ (P = 0.024, 0.004, respectively, paired t-test). Detectable blood oxygenation change was confirmed by finding SS susceptibility decreased from baseline to post-ACZ (P < 0.001, paired t-test), while MCA susceptibility did not change significantly (P = 0.67, paired t-test). DATA
CONCLUSION: These results suggest QSM is sensitive to dynamic OEF modulation during hemodynamic augmentation. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2019;50:175-182.
© 2018 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  CVR; QSM; acetazolamide; oximetry; stroke

Year:  2018        PMID: 30390367     DOI: 10.1002/jmri.26546

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  4 in total

Review 1.  MR Thermometry in Cerebrovascular Disease: Physiologic Basis, Hemodynamic Dependence, and a New Frontier in Stroke Imaging.

Authors:  S Dehkharghani; D Qiu
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-05       Impact factor: 3.825

Review 2.  Cerebral oxygen extraction fraction MRI: Techniques and applications.

Authors:  Dengrong Jiang; Hanzhang Lu
Journal:  Magn Reson Med       Date:  2022-05-05       Impact factor: 3.737

3.  Acetazolamide-Loaded Dynamic 7T MR Quantitative Susceptibility Mapping in Major Cerebral Artery Steno-Occlusive Disease: Comparison with PET.

Authors:  K Fujimoto; I Uwano; M Sasaki; S Oshida; S Tsutsui; W Yanagihara; S Fujiwara; M Kobayashi; Y Kubo; K Yoshida; K Terasaki; K Ogasawara
Journal:  AJNR Am J Neuroradiol       Date:  2020-04-16       Impact factor: 3.825

4.  Cerebral oxygen metabolism in adults with sickle cell disease.

Authors:  Lena Václavů; Jan Petr; Esben Thade Petersen; Henri J M M Mutsaerts; Charles B L Majoie; John C Wood; Ed VanBavel; Aart J Nederveen; Bart J Biemond
Journal:  Am J Hematol       Date:  2020-01-28       Impact factor: 13.265

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.